GOVXHealthcare · BiotechnologyGOVX Stock Forecast: GeoVax Labs, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering GeoVax Labs, Inc. hold a median 12-month price target of $10 — +1448.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 21 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
GOVX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores GeoVax Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
GOVX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GOVX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +1448.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Apr 2026 | D. Boral Capital | Maintains | Hold | $1.00 |
| 19 Feb 2026 | D. Boral Capital | Downgrade | Hold | — |
| 21 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 19 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 17 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 2 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 31 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Dec 2024 | D. Boral Capital | Maintains | Buy | — |
| 20 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GOVX appears on the weeks it earns a place.
GOVX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
GeoVax Labs, Inc. (GOVX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- 1.3×
- Price / book
- 2.5×
- EV / EBITDA
- −0.1×
Cheaper than 76% of US stocks
Cheaper than 65% of US stocks
Cheaper than 39% of US stocks
Cheaper than 61% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −862.3%
- Net margin
- 0.0%
Higher than 6% of US stocks
Higher than 30% of US stocks
- Return on equity
- −891.6%
- Return on assets
- −256.8%
- Dividend yield
- —
Higher than 2% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
GOVX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own GeoVax Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about GOVX stock
What is the GOVX stock price forecast for 2026-2027?
The 2 Wall Street analysts covering GeoVax Labs, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GOVX stock a buy right now?
Of the 2 analysts covering GeoVax Labs, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GeoVax Labs, Inc. 29 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GOVX?
As at 21 Aug 2026, GeoVax Labs, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
Will GOVX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1448.0% from the last close, and Ticker Nerd's factor model ranks GeoVax Labs, Inc. 29 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GOVX stock forecast for 2030?
No analyst covering GeoVax Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GOVX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
How has GOVX stock performed over the past year?
GeoVax Labs, Inc. returned -96.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does GeoVax Labs, Inc. do?
GeoVax Labs Inc. is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies.
About GeoVax Labs, Inc.
GeoVax Labs Inc. is a clinical-stage biotechnology company specializing in the development of human vaccines and immunotherapies. Headquartered in Smyrna, Georgia and founded in 1988, the company focuses on addressing unmet medical needs in infectious diseases and oncology. GeoVax Labs Inc. leverages proprietary vaccine platforms to develop preventive vaccines against high-consequence pathogens, including hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, as well as Zika virus, malaria, and human immunodeficiency virus (HIV). In addition, the company is advancing therapeutic candidates targeting solid tumor cancers, using gene-directed and immune-activating approaches to enhance antitumor responses. Its pipeline includes next-generation vaccine candidates and cancer immunotherapies that are evaluated through clinical and preclinical programs. Operating within the broader biotechnology and health technology sectors, GeoVax Labs Inc. plays a specialized role in the market by focusing on complex, often neglected disease areas where robust immune protection or targeted immunotherapy can be particularly important for public health and clinical practice.
CEO Mr. David Alan Dodd · 19 employees · United States · https://www.geovax.com